(Q73520267)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

4 November 2019

main subject

1 reference

randomized controlled trial

inferred from title

1 reference

1 reference

1 reference

1 reference

Fontana RJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Israel J

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

LeClair P

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Banner BF

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Tortorelli K

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Grace N

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Levine RA

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Fiarman G

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Thiim M

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Tavill AS

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Bonkovsky HL

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 March 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

730-736

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

Natural history of hepatitis C

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Side effects of α interferon in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Response to interferon alpha therapy is influenced by the iron content of the liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Iron and chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Iron and chronic viral hepatitis: emerging evidence for an important interaction

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Interferon treatment of cirrhotic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Re-treatment of chronic hepatitis C with consensus interferon .

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Mutation analysis in hereditary hemochromatosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Measurements of iron status in patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Therapy of hepatitis C: Other options

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Haemochromatosis gene mutation in liver disease patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510310325

7 January 2021

Identifiers

DOI

10.1002/HEP.510310325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10706565%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference